🚀 VC round data is live in beta, check it out!
Urteste Valuation Multiples
Discover revenue and EBITDA valuation multiples for Urteste and similar public comparables like Read-Gene, Bionano Genomics, NRGene, EZZ Life Science and more.
Urteste Overview
About Urteste
Urteste SA specialises in the development of technology allowing the detection of cancers at the early stages of their development. The companies technology helps detect cancers by measuring the activity of the enzymes in urine. Urteste develops diagnostic tests for more than ten common cancers.
Founded
N/A
HQ
Employees
N/A
Website
Financials (FY)
EV
$19M
Urteste Financials
Urteste reported last fiscal year revenue of — and negative EBITDA of ($701K).
In the same fiscal year, Urteste generated ($83K) in gross profit, ($701K) in EBITDA losses, and had net loss of ($1M).
Urteste P&L
In the most recent fiscal year, Urteste reported revenue of — and EBITDA of ($701K).
Urteste expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | ($83K) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($701K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Urteste Stock Performance
Urteste has current market cap of $19M, and enterprise value of $19M.
Market Cap Evolution
Urteste's stock price is $12.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19M | $19M | 1.0% | XXX | XXX | XXX | $-0.66 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialUrteste Valuation Multiples
Urteste trades at (27.4x) EV/EBITDA.
Urteste Financial Valuation Multiples
As of April 18, 2026, Urteste has market cap of $19M and EV of $19M.
Equity research analysts estimate Urteste's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Urteste has a P/E ratio of (19.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (27.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (16.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (232.0x) | XXX | XXX | XXX |
| P/E | — | XXX | (19.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Urteste Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Urteste Margins & Growth Rates
Urteste's revenue in the last fiscal year grew by —.
Urteste Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (38%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Urteste Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Urteste | XXX | XXX | XXX | XXX | XXX | XXX |
| Read-Gene | XXX | XXX | XXX | XXX | XXX | XXX |
| Bionano Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| NRGene | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Biovica International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Urteste M&A Activity
Urteste acquired XXX companies to date.
Last acquisition by Urteste was on XXXXXXXX, XXXXX. Urteste acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Urteste
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialUrteste Investment Activity
Urteste invested in XXX companies to date.
Urteste made its latest investment on XXXXXXXX, XXXXX. Urteste invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Urteste
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Urteste
| Where is Urteste headquartered? | Urteste is headquartered in Poland. |
| Is Urteste publicly listed? | Yes, Urteste is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Urteste? | Urteste trades under URT ticker. |
| When did Urteste go public? | Urteste went public in 2021. |
| Who are competitors of Urteste? | Urteste main competitors are Read-Gene, Bionano Genomics, NRGene, EZZ Life Science. |
| What is the current market cap of Urteste? | Urteste's current market cap is $19M. |
| Is Urteste profitable? | No, Urteste is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.